This study investigates the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and psychiatric adverse events (AEs) using data from the FDA Adverse Event Reporting System (FAERS) database. The analysis covers reports from Q1 2004 to Q1 2023, focusing on psychiatric AEs. Key findings include: 1. **Prevalence and Demographics**: Psychiatric AEs accounted for 4.55% of all AEs associated with GLP-1 RAs, with a higher proportion reported in women (65.89%) compared to men (30.96%). The median age of patients was 56 years. 2. **Onset Time**: The median time to onset of psychiatric AEs was 31 days, with exenatide showing the longest median onset time (45 days) compared to other GLP-1 RAs. 3. **Disproportionality Analysis**: Eight categories of psychiatric AEs were identified as highly associated with GLP-1 RAs, including nervousness, stress, eating disorders, fear of injection, sleep disorders, binge eating, fear of eating, and self-induced vomiting. These AEs were significantly more common in patients treated with GLP-1 RAs compared to the general population. 4. **Drug-Specific Analysis**: Liraglutide, semaglutide, and tirzepatide showed lower risks of psychiatric AEs compared to exenatide, dulaglutide, and liraglutide, respectively. 5. **Clinical Implications**: The study highlights the need for clinicians to monitor patients for psychiatric AEs, especially when using exenatide, and to provide early intervention for optimal risk management. The study underscores the importance of further research to validate these findings and to explore the underlying mechanisms of GLP-1 RA-related psychiatric AEs.This study investigates the association between glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and psychiatric adverse events (AEs) using data from the FDA Adverse Event Reporting System (FAERS) database. The analysis covers reports from Q1 2004 to Q1 2023, focusing on psychiatric AEs. Key findings include: 1. **Prevalence and Demographics**: Psychiatric AEs accounted for 4.55% of all AEs associated with GLP-1 RAs, with a higher proportion reported in women (65.89%) compared to men (30.96%). The median age of patients was 56 years. 2. **Onset Time**: The median time to onset of psychiatric AEs was 31 days, with exenatide showing the longest median onset time (45 days) compared to other GLP-1 RAs. 3. **Disproportionality Analysis**: Eight categories of psychiatric AEs were identified as highly associated with GLP-1 RAs, including nervousness, stress, eating disorders, fear of injection, sleep disorders, binge eating, fear of eating, and self-induced vomiting. These AEs were significantly more common in patients treated with GLP-1 RAs compared to the general population. 4. **Drug-Specific Analysis**: Liraglutide, semaglutide, and tirzepatide showed lower risks of psychiatric AEs compared to exenatide, dulaglutide, and liraglutide, respectively. 5. **Clinical Implications**: The study highlights the need for clinicians to monitor patients for psychiatric AEs, especially when using exenatide, and to provide early intervention for optimal risk management. The study underscores the importance of further research to validate these findings and to explore the underlying mechanisms of GLP-1 RA-related psychiatric AEs.